ArticleSensors (Basel, Switzerland)2020
Measurement of Early Disease Blueberries Based on Vis/NIR Hyperspectral Imaging System.
Article in Sensors (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 39 citations in OpenAlex.
- Advanced Spectroscopic, Imaging, and Nanotechnology Tools for Diagnosing Fungal Diseases in Fruits.Food science & nutrition · 2026Review
- Recent advances in plant disease detection: challenges and opportunities.Plant methods · 2025Review
- The Potential Application of Visible-Near Infrared (Vis-NIR) Hyperspectral Imaging for Classifying Typical Defective Goji Berry (Foods (Basel, Switzerland) · 2024Article
- Early diagnosis of Cladosporium fulvum in greenhouse tomato plants based on visible/near-infrared (VIS/NIR) and near-infrared (NIR) data fusion.Scientific reports · 2024Article
- Blueberry bruise non-destructive detection based on hyperspectral information fusion combined with multi-strategy improved Beluga Whale Optimization algorithm.Frontiers in plant science · 2024Article
- Non-destructive pre-symptomatic detection of gray mold infection in kiwifruit using hyperspectral data and chemometrics.Plant methods · 2023Article
- Maturity Stage Discrimination ofMolecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Blueberries, which are rich in nutrition, are susceptible to fungal infection during postharvest or storage. However, early detection of diseases in blueberry is challenging because of their opaque appearance and the inconspicuousness of spots in the early stage of disease. The goal of this study was to investigate the potential of hyperspectral imaging over the spectral range of 400-1000 nm to discriminate early disease in blueberries. Scanning electron microscope observation verified that fungal damage to the cellular structure takes place during the early stages. A total of 400 hyperspectral images, 200 samples each of healthy and early disease groups, were collected to obtain mean spectra of each blueberry samples. Spectral correlation analysis was performed to select an effective spectral range. Partial least square discrimination analysis (PLSDA) models were developed using two types of spectral range (i.e., full wavelength range of 400-1000 nm and effective spectral range of 685-1000 nm). The results showed that the effective spectral range made it possible to provide better classification results due to the elimination of the influence of irrelevant variables. Moreover, the effective spectral range combined with an autoscale preprocessing method was able to obtain optimal classification accuracies, with recognition rates of 100% and 99% for healthy and early disease blueberries. This study demonstrated that it is feasible to use hyperspectral imaging to measure early disease blueberries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.